ClinicalTrials.gg
RecruitingNCT07299422Updated Sep 29, 2026

A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus

A Phase 2 interventional study of SHR-2173 Injection and SHR-2173 Injection Placebo in Systemic Lupus Erythematosus, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Sep 29, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
34th of 245
248 · median 36
Started
2026
with 55 others
Phase 2
33 of 266
14 open now
Primary completion
2028-03
later than 145 of 190 live
Registered
210th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 34th largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 145 of the 190 other live ones, and was the 210th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

162 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, multi-center, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in adult participants with active Systemic Lupus Erythematosus (SLE), including a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and a 12-week safety follow-up period. Approximately 245 SLE patients will be included.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants aged 18 through 65 years (including boundary value)at the time of screening.
  2. The (BMI) ≥18 kg/m ² at the time of screening.
  3. Diagnosed with SLE for at least 6 months prior to screening.
  4. ANA≥1:80, or anti-dsDNA antibodies and/or anti-Sm antibodies above the as determined by a central laboratory at the time of screening.
  5. High disease activity at screening and at baseline.
  6. Currently receiving at least one or more of the following standard therapies for SLE at stable doses: oral (OCS), antimalarial drugs, and conventional .
  7. Participants thoroughly understand the content, process and possible adverse reactions before the trial, and voluntarily sign the written Form (ICF).
  8. Female subjects with fertility or male participants whose partners are women of childbearing age must avoid donating sperm/eggs from the date of signing the ICF until 12 weeks after the last study medication, and agree to take measures as specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. The presence of any of the following medical histories or comorbidities: a) Severe lupus-related kidney disease and/or kidney damage; b) Active neuropsychiatric SLE occurred 6 months prior to screening; c) , inflammatory or joint diseases other than SLE and LN that may interfere with the interpretation of the test results or clinical assessment, including but not limited to rheumatoid arthritis, overlap syndrome, psoriasis/psoriatic arthritis, eczema, inflammatory bowel disease, and any other vasculitis; d) There was catastrophic or severe antiphospholipid syndrome within 12 months prior to screening; e) Have a history of progressive multifocal leukoencephalopathy (PML); f) Have a history of organ transplantation.
  2. Use any of the following medications /treatments or participate in a clinical trial: a) Previously received gene therapy such as CAR-T or T-cell Engager (TCE) ; b) Received anti-CD20 monoclonal antibody within 6 months and other B-cell or plasma cell depletion treatments within 6 to 12 months prior to randomization; c) Received biologic therapy targeting BAFF, APRIL or interferon receptor within 12 weeks prior to randomization; d) Received Alkylating agents within 12 weeks prior to randomization; e) Received any other biological agents for the treatment of SLE within 12 weeks prior to randomization; f) Received inhibitors of Janus kinase (JAK), Bruton tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2) within 12 weeks prior to randomization; g) Received intra-articular, intramuscular or intravenous for SLE within 4 weeks prior to randomization; h) Received a live/attenuated within 4 weeks prior to randomization or planned to receive it during the trial period.
  3. The presence of the following tumor risks or accompanied by other poorly controlled serious or chronic diseases: a) Suffering from malignant tumors or having a history of malignant tumors; b) Accompanying other poorly controlled serious or chronic diseases during or at the time of screening, including but not limited to endocrine diseases, cardiovascular diseases, neurological/mental disorders, kidney diseases, severe digestive system diseases, severe respiratory system diseases, neurological diseases, and other serious liver, gallbladder, metabolic or lymphatic system diseases, etc.
  4. Infection-related medical history and examinations: a) Herpes zoster infection meets one of the following conditions: 1) A history of systemic herpes zoster, such as disseminated herpes zoster, herpetic encephalitis or ocular herpes zoster involving the retina; 2) Recurrent herpes zoster that has occurred twice or more within two years; 3) The herpes zoster infection has not completely subsided within 12 weeks before screening; b) Tuberculosis (TB) or occult tuberculosis infection; c) A history of primary immunodeficiency, splenectomy, and any potential conditions that make participants susceptible to infection; d) A history of repeated infections requiring hospitalization and intravenous antibiotics; e) Hospitalization and/or intravenous anti-infective treatment were required within 8 weeks prior to randomization, or any infection that required oral anti-infective treatment within 2 weeks prior to randomization; f) Positive test results for any of the following: surface antigen (HBsAg), virus antibody, Treponema pallidum antibody or (HIV); If the test result is negative for HBsAg but positive for hepatitis B core antibody (HBcAb), regardless of whether the hepatitis B surface antibody (HBsAb) is positive or negative, HBV-DNA testing is required to determine the situation: if HBV-DNA is positive, participants should be excluded. Participants can be included if HBV-DNA is negative.
  5. General situation: a) Pregnant or lactating women; b) Having a history of alcohol abuse or illegal drug abuse within one year prior to screening; c) Individuals with allergic constitutions, or those known to be intolerant or allergic to any component of the drug; d) Participants who have undergone major surgeries within the 3 months prior to screening, or those who plan to undergo major surgeries during the trial period; e) Investigators determine that there are circumstances that affect the safety and efficacy evaluation of the investigational drug, or other circumstances not appropriate for participation in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    SHR-2173 Injection Group

    Drug: SHR-2173 Injection

  • Placebo comparator
    SHR-2173 Injection Placebo Group

    Drug: SHR-2173 Injection Placebo

Interventions

  • SHR-2173 injection in different doses.

  • DrugSHR-2173 Injection Placebo

    SHR-2173 injection placebo.

06

What researchers measure

Primary outcomes

  1. The proportion of participants achieving Systemic Lupus Erythematosus Responder Index-4 (SRI-4) at Week 24.

    Time frame: At Week 24.

Secondary outcomes

  1. The proportion of participants achieving SRI-4.

    Time frame: Up to Week 48.

  2. The proportion of participants achieving British Isles Lupus Assessment Group(BILAG) based Composite Lupus Assessment (BICLA).

    Time frame: Up to Week 48.

  3. The proportion of participants with a ≥ 4-point decrease from baseline in SLE Disease Activity Index 2000 (SLEDAI-2K).

    Time frame: Up to Week 48.

  4. The proportion of participants achieving SRI-4 on low-dose corticosteroids in the protocol.

    Time frame: Up to Week 48.

  5. The proportion of participants with a daily prednisone (or equivalent) dose of ≤ 7.5 mg (limited to those with baseline corticosteroids > 7.5 mg/day).

    Time frame: Up to Week 48.

  6. Change from baseline in Patient's Global Assessment(PGA).

    Time frame: Up to Week 48.

  7. The proportion of participants achieving Lupus Low Disease Activity State (LLDAS) in the protocol.

    Time frame: Up to Week 48.

  8. The proportion of participants achieving Definitions of Remission In SLE (DORIS) in the protocol.

    Time frame: Up to Week 48.

  9. Change from baseline in the level of anti-dsDNA antibody.

    Time frame: Up to Week 48.

  10. Change from baseline in the level of complement (C3, C4).

    Time frame: Up to Week 48.

  11. Change from baseline in the level of CD19+B cells.

    Time frame: Up to Week 48.

  12. Change from baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in the protocol.

    Time frame: Up to Week 48.

  13. Changes from baseline in SLE-Specific Quality-Of-Life (SLEQOL) in the protocol.

    Time frame: Up to Week 48.

  14. Adverse events, vital signs, physical examinations, laboratory tests, 12-lead electrocardiograms, etc.

    Time frame: The entire process of the trial , about two years.

07

Study locations

2 of 2 sites recruiting
  • Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100005, China
    Recruiting
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200127, China
    Recruiting
    • Liangjing Lv · Contactlu_liangjing@163.com · +86-021-53882314
    • Liangjing Lv · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Mar 2028, 23 months after the start.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 23 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Dec 23, 2025
StartActual
Apr 3, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Nov 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
1 added
What changed in the outcomes
  • AddedAdverse events, vital signs, physical examinations, laboratory tests, 12-lead electrocardiograms, etc.Time frame: The entire process of the trial , about two years.
Sep 29, 2026
Contact
Study contact changed: s•••@hengrui.com · •••2973→q•••@hengrui.com · •••2973. See the current contact
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedAdverse events, vital signs, physical examinations, laboratory tests, 12-lead electrocardiograms, etc.Time frame: The entire process of the trial , about two years.
    Contact Study contact changed: s•••@hengrui.com · •••2973→q•••@hengrui.com · •••2973. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07299422
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Apr 3, 2026
Primary completion
Mar 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Qiuna Du, MD
Contact
qiuna.du@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2173

Start the discussion